Compare Novartis AG (NVS) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Prudential PLC — how do they compare? Novartis AG trades at $142.04 (market cap $274.00B), while Prudential PLC trades at $24.03 (market cap $28.76B). The key difference: Novartis AG is far larger — about 9.5× Prudential PLC's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Prudential PLC for 119 Days on average.
| NVS | PUK | |
|---|---|---|
Market Cap | $274.00B | $28.76B |
Volume | 1,852,137 | 1,285,651 |
Sector | Health | Financials |
52-Week High | $168.62 | $33.61 |
52-Week Low | $121.80 | $23.54 |
Typical Hold Time | 82 Days | 119 Days |
Enterprise Value | $315.32B | $28.30B |
Dividend Yield | 3.31% | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
PUK trades at $23.88, down 2.93% over 24 hours, amid a bearish technical signal. The company reported strong revenue growth to $27.39B in 2025 and net income of $3.98B, with a net margin of 14.52%. Recent earnings show mixed quarterly results, with two beats and two misses versus expectations. Analyst consensus is moderately bullish, with 50% buy ratings. The firm is executing a strategic overhaul, including a $3B capital rotation plan and exiting certain markets to sharpen focus.
The outlook is cautiously optimistic given solid profitability and strategic initiatives, but near-term headwinds include earnings volatility and bearish technical indicators. Risks involve execution of the restructuring and macroeconomic pressures. The stock presents a value opportunity with a low P/E of 8.28, though investors should weigh the mixed earnings record against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
